HANSA BIOPHARMA AB

Hansa Biopharma’s latest trading dip hides a bullish trend: near its 200‑day SMA, strong pipeline growth and EU‑level approvals could fuel a rebound for investors.

Hansa Biopharma shares rise 6% as Idefirix gets oral spot at ASN Kidney Week and IND for HNSA‑5487 launched, boosting prospects for transplant & GBS therapies.